By inhibiting the interaction between the immune checkpoints expressed on T cells, such as PD-1 and CTLA-4 and their ligands (PD-L1 and CD80/86) expressed by tumor cells/antigen-presenting cells, ICIs induce the activation of T effector cells targeting tumor cells (5). Here, CD80 is linked to neoplasm.